Hyperpolarized 13C magnetic resonance reveals early- and late-onset changes to in vivo pyruvate metabolism in the failing heart

Impaired energy metabolism has been implicated in the pathogenesis of heart failure. Hyperpolarized 13C magnetic resonance (MR), in which 13C‐labelled metabolites are followed using MR imaging (MRI) or spectroscopy (MRS), has enabled non‐invasive assessment of pyruvate metabolism. We investigated the hypothesis that if we serially examined a model of heart failure using non‐invasive hyperpolarized [13C]pyruvate with MR, the profile of in vivo pyruvate oxidation would change throughout the course of the disease.

[1]  G. Radda,et al.  The Cycling of Acetyl-Coenzyme A Through Acetylcarnitine Buffers Cardiac Substrate Supply: A Hyperpolarized 13C Magnetic Resonance Study , 2012, Circulation. Cardiovascular imaging.

[2]  Albert P. Chen,et al.  Simultaneous investigation of cardiac pyruvate dehydrogenase flux, Krebs cycle metabolism and pH, using hyperpolarized [1,2‐13C2]pyruvate in vivo , 2012, NMR in biomedicine.

[3]  Michael A. Burke,et al.  Targeting myocardial substrate metabolism in heart failure: potential for new therapies , 2012, European journal of heart failure.

[4]  Albert P. Chen,et al.  Integrated Bloch‐Siegert B1 mapping and multislice imaging of hyperpolarized 13C pyruvate and bicarbonate in the heart , 2012, Magnetic resonance in medicine.

[5]  Kieran Clarke,et al.  Hyperpolarized Magnetic Resonance: A Novel Technique for the In Vivo Assessment of Cardiovascular Disease , 2011, Circulation.

[6]  C. Malloy,et al.  Could 13C MRI assist clinical decision‐making for patients with heart disease? , 2011, NMR in biomedicine.

[7]  G. Radda,et al.  Role of Pyruvate Dehydrogenase Inhibition in the Development of Hypertrophy in the Hyperthyroid Rat Heart: A Combined Magnetic Resonance Imaging and Hyperpolarized Magnetic Resonance Spectroscopy Study , 2011, Circulation.

[8]  G. Radda,et al.  Validation of the in vivo assessment of pyruvate dehydrogenase activity using hyperpolarised 13C MRS , 2011, NMR in biomedicine.

[9]  Graham A Wright,et al.  Rapid multislice imaging of hyperpolarized 13C pyruvate and bicarbonate in the heart , 2010, Magnetic resonance in medicine.

[10]  M. Budoff,et al.  Radiation exposure from cardiac imaging procedures: do the risks outweigh the benefits? , 2010, Journal of the American College of Cardiology.

[11]  K. Fleischmann.  Radiation Exposure from Cardiac Imaging Procedures , 2010 .

[12]  J. Knuuti,et al.  The adrenergic-fatty acid load in heart failure. , 2009, Journal of the American College of Cardiology.

[13]  Heinrich Taegtmeyer,et al.  Substrate–Enzyme Competition Attenuates Upregulated Anaplerotic Flux Through Malic Enzyme in Hypertrophied Rat Heart and Restores Triacylglyceride Content: Attenuating Upregulated Anaplerosis in Hypertrophy , 2009, Circulation research.

[14]  G. Radda,et al.  In vivo assessment of pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance , 2008, Proceedings of the National Academy of Sciences.

[15]  Peter Magnusson,et al.  Cardiac metabolism measured noninvasively by hyperpolarized 13C MRI , 2008, Magnetic resonance in medicine.

[16]  Craig R. Malloy,et al.  Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR , 2007, Proceedings of the National Academy of Sciences.

[17]  E. Lewandowski,et al.  Recruitment of Compensatory Pathways to Sustain Oxidative Flux With Reduced Carnitine Palmitoyltransferase I Activity Characterizes Inefficiency in Energy Metabolism in Hypertrophied Hearts , 2007, Circulation.

[18]  Stefan Neubauer,et al.  The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.

[19]  J. Horowitz,et al.  Time to address the cardiac metabolic "triple whammy" ischemic heart failure in diabetic patients. , 2006, Journal of the American College of Cardiology.

[20]  M. Thaning,et al.  Real-time metabolic imaging. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Clarke,et al.  Metabolic Modulation With Perhexiline in Chronic Heart Failure: A Randomized, Controlled Trial of Short-Term Use of a Novel Treatment , 2005, Circulation.

[22]  William C Stanley,et al.  Myocardial substrate metabolism in the normal and failing heart. , 2005, Physiological reviews.

[23]  R. Shannon,et al.  Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy , 2004, Circulation.

[24]  Robert G Weiss,et al.  Is the failing heart energy starved? On using chemical energy to support cardiac function. , 2004, Circulation research.

[25]  M. Chandler,et al.  Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. , 2004, Journal of molecular and cellular cardiology.

[26]  R. Shannon,et al.  The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. , 2004, Cardiovascular research.

[27]  J. Ardenkjær-Larsen,et al.  Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Fallen,et al.  Effect of Cardiac Resynchronization on Myocardial Efficiency and Regional Oxidative Metabolism , 2003, Circulation.

[29]  William C Stanley,et al.  Impaired Myocardial Fatty Acid Oxidation and Reduced Protein Expression of Retinoid X Receptor-&agr; in Pacing-Induced Heart Failure , 2002, Circulation.

[30]  O. Frazier,et al.  Metabolic Gene Expression in Fetal and Failing Human Heart , 2001, Circulation.

[31]  G. Bifulco,et al.  Activation and Mitochondrial Translocation of Protein Kinase Cδ Are Necessary for Insulin Stimulation of Pyruvate Dehydrogenase Complex Activity in Muscle and Liver Cells* , 2001, The Journal of Biological Chemistry.

[32]  T. Blackstad,et al.  Upregulation of the Cardiac Monocarboxylate Transporter MCT1 in a Rat Model of Congestive Heart Failure , 2001, Circulation.

[33]  E. Fallen,et al.  The Effects of β1-Blockade on Oxidative Metabolism and the Metabolic Cost of Ventricular Work in Patients With Left Ventricular Dysfunction , 2000 .

[34]  G. Lopaschuk,et al.  The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. , 2000, Circulation research.

[35]  S. Vatner,et al.  Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: a compensatory role for the parallel loss of creatine. , 1999, Circulation.

[36]  N. Price,et al.  The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. , 1999, The Biochemical journal.

[37]  F. Recchia,et al.  Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. , 1998, Circulation research.

[38]  D. Kelly,et al.  Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. , 1996, Circulation.

[39]  G. Radda,et al.  Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. , 1996, Journal of Clinical Investigation.

[40]  G. Paolisso,et al.  Total-body and myocardial substrate oxidation in congestive heart failure. , 1994, Metabolism: clinical and experimental.

[41]  G. Gambassi,et al.  Altered pyruvate dehydrogenase control and mitochondrial free Ca2+ in hearts of cardiomyopathic hamsters. , 1993, The American journal of physiology.

[42]  S. Neubauer,et al.  31P Magnetic Resonance Spectroscopy in Dilated Cardiomyopathy and Coronary Artery Disease: Altered Cardiac High‐Energy Phosphate Metabolism in Heart Failure , 1992, Circulation.

[43]  J. C. Gomez,et al.  Impaired Myocardial Fatty Acid Oxidation and Reduced Protein Expression of Retinoid X Receptor-alpha in Pacing-Induced Heart Failure , 2002 .

[44]  P Stanko,et al.  An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in Patients with Congestive Heart Failure. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  E. Fallen,et al.  The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study. , 2000, Circulation.